These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23115540)

  • 1. Efficacy and economic evaluation of a volume-based cathflo activase protocol versus a fixed-dose alteplase protocol for catheter occlusions in pediatric patients.
    Gilarde JA; Chung AM; Vidal R; Falkos S
    J Pediatr Pharmacol Ther; 2006 Oct; 11(4):237-44. PubMed ID: 23115540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
    Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
    J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
    Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
    Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions.
    Haymond J; Shalansky K; Jastrzebski J
    J Vasc Access; 2005; 6(2):76-82. PubMed ID: 16552689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters.
    Lyons MG; Phalen AG
    J Infus Nurs; 2014; 37(4):270-81. PubMed ID: 24983260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
    Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
    J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraluminal Volume Dose Alteplase for the Clearance of Occluded Peripherally Inserted Central Catheter Lines at a Long-Term Acute Care Hospital: Efficacy and Economic Impact.
    Sapienza SP; Ciaschini DR
    Hosp Pharm; 2015 Mar; 50(3):202-7. PubMed ID: 26405309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a single 2 mg dose or 4 mg double dose of alteplase for 50 occluded chest ports using a unique instillation technique.
    Sharma RP; Ree CJ; Ree A
    Int J Angiol; 2008; 17(3):125-8. PubMed ID: 22477414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteplase (Cathflo Activase).
    Middleton G; Ruzevick B
    Clin J Oncol Nurs; 2004 Aug; 8(4):417-8, 420. PubMed ID: 15354930
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices.
    Davis SN; Vermeulen L; Banton J; Schwartz BS; Williams EC
    Am J Health Syst Pharm; 2000 Jun; 57(11):1039-45. PubMed ID: 10876745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteplase for blood flow restoration in hemodialysis catheters: a multicenter, randomized, prospective study comparing "dwell" versus "push" administration.
    Vercaigne LM; Zacharias J; Bernstein KN
    Clin Nephrol; 2012 Oct; 78(4):287-96. PubMed ID: 22541682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
    Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
    J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a Nurse-Led Protocol on Time to Treatment of Partial Occlusions in Central Venous Access Devices in Pediatric Oncology.
    Hunter A; Cunningham KS; Yuen C; Jensen K; Afzal A; Benzies K
    J Pediatr Oncol Nurs; 2020; 37(5):305-312. PubMed ID: 32639196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
    Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
    J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality Improvement Initiative Reduces the Occurrence of Complications in Peripherally Inserted Central Catheters.
    Walters B; Price C
    J Infus Nurs; 2019; 42(1):29-36. PubMed ID: 30589718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.